Efficacy of Enfortumab Vedotin Ineligible criTeriA (EVITA) in advanced urothelial carcinoma DOI
Takafumi Fukushima, Kazuyuki Numakura,

M. Shiohara

et al.

Published: April 3, 2025

Abstract Enfortumab Vedotin Ineligible criTeriA (EVITA) were proposed for the selection of patients to receive enfortumab vedotin (EV) and pembrolizumab treatment. However, usefulness these criteria has not been verified. We investigated efficacy ofthe EVITA in with unresectable or metastatic urothelial carcinoma (UC) who treated EV monotherapy real-world practice. retrospectively analyzed data from 301 unresectableor UC underwent first-line chemotherapy.We evaluated numbers fulfilling EVITAand relationship safety monotherapy. Of patients, 4.3% (n = 13) fulfilled chemotherapy. The major factor contributing a higher score was renal dysfunction. 135 subsequent therapy, number had no influence on frequency all-grade grade ≥3 adverse events. Oncological outcomes associated EVITA. In conclusion, we observed 14.8% at time respectively. could be confirmed.

Language: Английский

Editorial Comment to “Impact of Skin Adverse Events on Prognosis in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin: A Real‐World Multicenter Study” DOI

Nozomi Hayakawa,

Eiji Kikuchi

International Journal of Urology, Journal Year: 2025, Volume and Issue: unknown

Published: April 7, 2025

Language: Английский

Citations

0
Efficacy of Enfortumab Vedotin Ineligible criTeriA (EVITA) in advanced urothelial carcinoma DOI
Takafumi Fukushima, Kazuyuki Numakura,

M. Shiohara

et al.

Published: April 3, 2025

Abstract Enfortumab Vedotin Ineligible criTeriA (EVITA) were proposed for the selection of patients to receive enfortumab vedotin (EV) and pembrolizumab treatment. However, usefulness these criteria has not been verified. We investigated efficacy ofthe EVITA in with unresectable or metastatic urothelial carcinoma (UC) who treated EV monotherapy real-world practice. retrospectively analyzed data from 301 unresectableor UC underwent first-line chemotherapy.We evaluated numbers fulfilling EVITAand relationship safety monotherapy. Of patients, 4.3% (n = 13) fulfilled chemotherapy. The major factor contributing a higher score was renal dysfunction. 135 subsequent therapy, number had no influence on frequency all-grade grade ≥3 adverse events. Oncological outcomes associated EVITA. In conclusion, we observed 14.8% at time respectively. could be confirmed.

Language: Английский

Citations

0